Corcept Therapeutics (CORT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $182.5 million, up 48% year-over-year, driven by higher sales volumes, price increases, and increased Korlym prescriptions.

• Net income for Q3 2024 was $47.2 million, a 51% increase from $31.4 million in Q3 2023, with diluted EPS of $0.41, up from $0.28.

• Cash and investments totaled $547.6 million as of September 30, 2024, up from $425.4 million at year-end 2023.

• Raised 2024 revenue guidance to $675–$700 million, reflecting strong commercial performance and volume growth.

• Positive phase III results for relacorilant in Cushing syndrome support NDA submission by year-end, with multiple late-stage clinical milestones expected in Q4.

Financial highlights

• Q3 2024 product revenue: $182.5 million (Q3 2023: $123.6 million); nine months YTD: $493.2 million (2023: $347.0 million).

• Net income for Q3 2024 was $47.2 million, compared to $31.4 million in Q3 2023.

• Operating expenses for Q3 2024: $135.9 million, up from $92.4 million in Q3 2023, mainly due to increased R&D and SG&A.

• Cash and investments grew to $547.6 million from $492.5 million at the end of Q2 2024.

• Repurchased $23.4 million of common stock during the quarter.

Outlook and guidance

• 2024 revenue guidance increased to $675–$700 million, reflecting continued strong growth.

• NDA for relacorilant in Cushing's syndrome to be submitted by year-end; key clinical trial results expected in Q4.

• Anticipates substantial volume growth in the near and long term, with a target to become a $3 billion business in five years.

• R&D and SG&A expenses expected to be higher in 2024 as clinical and commercial activities expand.

• Company expects to fund operations and planned R&D activities over the next 12 months and beyond without needing to raise additional funds.